Sign In
11 Mar 2011 14:52
11 March 2011
Plethora Solutions Holdings plc
("Plethora" or "the Company")
Board Changes
The company regrets to announce that, as a result of a serious medical condition, the CEO Stephen Powell will be taking leave of absence. Consequently, Ronald Openshaw has been appointed Interim CEO.
-Ends-
Enquiries:
Plethora Solutions Ronald Openshaw | Tel : +44(0) 20 3077 5400 |
Daniel Stewart (Nominated Adviser) Antony Legge | Tel : +44(0) 20 7776 6550
|
Hansard Communications Adam Reynolds/Nicholas Nelson | Tel: +44(0) 20 7245 1100
|
About Plethora:
Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder (PSD506), stress urinary incontinence (PSD503 - Virgafem), interstitial cystitis (PSD597 - Urolieve) erectile dysfunction (PSD510) and premature ejaculation (PSD502).
Plethora's subsidiary, The Urology Company Limited, was established in 2009 to market and distribute a range of branded and generic pharmaceutical products, pharmaceutical specials, medical devices and nutritional supplements for the treatment of urology, andrology and obstetric conditions.
The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.uk and www.theurologyco.com
Follow the stocks
